September 28, 2020

The Niche

Knoepfler lab stem cell blog

Regenerative Medicine Advanced Therapy (RMAT) designation list

2 min read

Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several diseases including related to vision loss and Parkinson’s Disease. David Cyranoski over at Nature reports on a new, different stem cell clinical effort in Japan for vision loss with …Read More

4 min read

There is real hope for treating spinal cord injury with stem cell-based therapies in the future. However, unfortunately regulators in Japan have taken a major misstep in approving a not-ready-for-primetime mesenchymal stem cell (MSC)-based approach to spinal cord injury. Their decision is dangerous and unwise. In a Nature piece (linked to above) by David Cyranoski we learn that the MSC therapy in question is still unproven. There are only limited data available to support it, which are not from rigorous studies. The claimed outcomes …Read More